Last reviewed · How we verify

NCT03809728: i-BANK

IDENTIFICATION OF PROGNOSTIC AND PREDICTIVE BIOMARKERS IN INFLAMMATORY BOWEL DISEASE

Recruiting now NA Last updated 7 February 2024
What this trial tests

NA trial testing endoscopic biopsy in Inflammatory Bowel Diseases in 1,000 participants. Currently enrolling.

Timeline
10 December 2019
Primary endpoint
10 December 2034
10 December 2034

Quick facts

Lead sponsorCentral Hospital, Nancy, France
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment1,000
Start date10 December 2019
Primary completion10 December 2034
Estimated completion10 December 2034
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with Inflammatory Bowel Diseases or Crohn Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Interventional study of a group of patients with an inflammatory bowel disease (IBD; Crohn's disease (CD) or ulcerative colitis (UC)) to identify predictive and prognostic biomarkers of natural history and response to biotherapies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges.
    Noviello D, Mager R, Roda G, Borroni RG, et al · · 2021 · cited 105× · PMID 34079536 · DOI 10.3389/fimmu.2021.611256

Verify or expand the search:

Other recruiting trials for Inflammatory Bowel Diseases

Currently open trials in the same condition.

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03809728.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing